XOMA Appreciateing On Positive News

According to UCB, approximately 1.3 million Americans suffer from rheumatoid arthritis and Crohn's disease afflicts approximately 500,000 people in the U.S.

XOMA discovers, develops and manufactures therapeutic antibody and other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases. The Company's proprietary product pipeline includes XOMA 052, an anti-IL-1 beta antibody, and XOMA 3AB, a biodefense anti-botulism antibody candidate.